NK- and T-cell lymphoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 11:08, 17 April 2023 by Jwarner (talk | contribs) (Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main NKTCL page for current regimens.

1 regimens on this page
1 variants on this page


Relapsed or refractory

Pembrolizumab monotherapy

Regimen

Study Evidence
Kwong et al. 2017 Case series

Note: prospective trials are underway.

Immunotherapy

21-day cycles

References

  1. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, Phipps C, Tse E. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 Apr 27;129(17):2437-2442. Epub 2017 Feb 10. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=NK-_and_T-cell_lymphoma_-_historical&oldid=67946"